Teva Targets 30% Operating Margin by 2027 as Generics Revenue Falls 13%
Teva posted a 13% decline in generics revenue, excluding Japan, and flagged potential IRA-driven inventory and pricing shifts for AUSTEDO in late 2026. The company reaffirmed its 2027 goal of a 30% operating margin, cost savings from transformation initiatives and highlighted $3.7 billion cash with robust free cash flow plans.
1. Generics Market Performance
Teva's generics segment saw a 13% revenue decline excluding Japan, with flat performance when also excluding generic Revlimid. Management highlighted uncertainty around how the Inflation Reduction Act may affect AUSTEDO inventory levels and pricing in the fourth quarter of 2026.
2. 2027 Financial Targets
The company reaffirmed its commitment to achieve a 30% operating margin by 2027, driven by ongoing transformation programs projected to deliver substantial cost savings and margin improvements.
3. Emalex Acquisition and Ecopipam
The $700 million Emalex acquisition strengthens Teva's CNS franchise with ecopipam targeting pediatric Tourette syndrome. Teva plans a dedicated pediatric sales force, leveraging its movement disorder expertise and orphan drug pricing to address an unmet need among approximately 100,000 children.
4. Capital Allocation and Liquidity
Teva ended the quarter with $3.7 billion in cash and forecasts robust free cash flow generation. Its capital allocation strategy prioritizes maximizing shareholder value through potential share buybacks while maintaining a target net debt to EBITDA leverage of two times.